CryoLife Awarded U. S. Patent for BioFoam
Potential Product Applications Include Battlefield Injuries, Internal Organ and Vascular Tissue Sealing, and Tissue Augmentation
CryoLife, Inc. announced that it has been awarded a patent by the U.S. Patent Office for BioFoam(R), a protein hydrogel foam for rapidly filling and sealing open wounds. Scientists at CryoLife invented and developed this product as a hemostatic agent and tissue and organ sealant. CryoLife is continuing to develop BioFoam as an organ and tissue sealant. Other applications the company may explore include vascular sealing and tissue augmentation.
Additionally, CryoLife has received funds from the U.S. Department of Defense (DoD), as part of its battlefield trauma program, for the development of protein hydrogel as a product to limit blood loss in soldiers injured in battle.
According to the company, BioFoam contains an expansion agent, and rapidly fills wounds when dispensed. It is easily applied and could potentially be used intraoperatively to control internal organ hemorrhage, limit blood loss, reduce the need for future operations, as well as to seal open wounds to improve outcomes in penetrating abdominal and chest injury.
Other news from the department research and development
